PHGE Overview

BiomX Inc. is a clinical stage product discovery company developing products using both natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases, such as diabetic foot infections, or DFI. Bacteriophage or phage are bacterial, species-specific, strain-limited viruses that infect, amplify and kill the target bacteria and are considered inert to mammalian cells. By utilizing proprietary combinations of naturally occurring phage and creating novel phage using synthetic biology, it develops phage-based therapies intended to address large-market diseases. The Company offers two phage-based product types: Fixed cocktail therapy and Personalized therapy. Its ongoing programs include BX011 and BX211. BX011 is a fixed multi-phage cocktail, for the treatment of DFI associated with Staphylococcus aureus (S. aureus). BX211 is a phage therapy for the treatment of Diabetic Foot Osteomyelitis (DFO) associated with S. aureus.

Wall Street analysts forecast PHGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PHGE is26.00 USD with a low forecast of 26.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BiomX Inc revenue for the last quarter amounts to -7.20M USD, decreased -23.47

BiomX Inc. EPS for the last quarter amounts to -4386000.00 USD, decreased -30.38

BiomX Inc (PHGE) has 20 emplpoyees as of April 20 2026.

Today PHGE has the market capitalization of 12.04M USD.